Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 5011 (MIR5011)
- Target
- MIR5011
- Molecular classification
- MicroRNA, Non-coding RNA, Regulatory RNA
01
Overview
microRNA 5011 (MIR5011) is a small, non-coding RNA molecule transcribed by the human genome. It functions as a post-transcriptional regulator, binding to specific sequences in the 3’ untranslated regions (UTRs) of mRNAs and promoting their degradation or inhibiting their translation, thereby modulating gene expression. Expression of MIR5011 is reduced in various tumor tissues, including colorectal cancer, and it is predicted to act as a tumor suppressor by downregulating genes involved in oncogenic signaling pathways such as TGF-beta and Wnt. Its regulatory effects span multiple cellular processes, including cell cycle progression, cell death, and signal transduction. While not directly targeted by approved drugs, MIR5011 and related microRNAs are the focus of ongoing research into RNA-based biomarkers and therapeutics for cancer and other diseases
- Other names
- MIR5011hsa-mir-5011miR-5011-5p
02
Mechanism of action
Post-transcriptional repression of target mRNAs Regulation of cancer-related signaling by downregulation of key genes (e.g., SMAD6, SMAD7, WNT3A, LRP6, TCF4, GSK3B, MAPK3, PAK2)
03
Biological functions
Gene expression regulationCell cycle modulationCell death regulationSignal transduction involvement (via targeting genes in TGF-beta, Wnt, PI3K-Akt, Ras, mTOR pathways)Cell junction assemblyTranscription regulation (RNA polymerase II promoter)
04
Disease associations
Cancer (especially colorectal cancer, breast cancer, glioma, gastric cancer)Tumor progression and suppressionAdditional roles in neurological and muscular disease are suggested, but less well-characterized
05
Safety considerations
Therapeutic targeting of microRNAs poses risks of off-target gene regulation, immune activation, and unintended cellular effects due to broad regulatory roles of miRNAs
06
Biomarkers
Downregulated expression in tumor tissue (colorectal cancer, gastric cancer, glioma, blood in cervical dystonia)Potential biomarker for cancer diagnosis or progression, especially colorectal cancer
Beyond the preview
Go deeper on microRNA 5011 (MIR5011).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA 5011 (MIR5011).